Dana-Farber scientists receive Stand Up To Cancer-Farrah Fawcett Foundation Grant for research in novel vaccine for HPV-associated cancers
April 07, 2014
Dana-Farber researchers have received a three-year, $1.2 million research grant from Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation to lead a team in developing and testing new vaccines for patients with cancers linked to the human papillomavirus (HPV). 
'You Have Us' campaign shows state-of-the-art treatment for your cancer
Innovative research and therapies ... personalized treatment and care ... specialists who only treat your particular cancer. Our communications campaign highlights the reasons why Dana-Farber/Brigham and Women's Cancer Center is right for you.View the campaign
Scientists find potential drug targets in deadly pediatric brain tumors
April 06, 2014
Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new study from scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and McGill University. The findings, published in Nature Genetics, identify potential new targets for drug treatments. Study identifies lung cancer patients likely to benefit from potential immune system-based therapy
April 06, 2014
Investigators at Dana-Farber led by Leena Gandhi, MD, PhD, report a promising way of predicting which patients with non-small cell lung cancer (NSCLC) are most likely to benefit from a drug that frees up an immune system attack on tumor cells. Dana-Farber Cancer Institute and Steward St. Elizabeth’s Medical Center join to provide integrated cancer care
March 31, 2014
Beginning this summer, Dana-Farber Cancer Institute will provide hematology and medical oncology care under a new agreement at St. Elizabeth's Medical Center, a part of the Steward Health Care System. 
No comments:
Post a Comment